CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Status:
Completed
Trial end date:
2020-04-23
Target enrollment:
Participant gender:
Summary
Sometimes researchers change the DNA (genetic material in cells) of donated T cells (white
blood cells that support the immune system) using a process called "gene transfer." Gene
transfer involves drawing blood from the patient, and then separating out the T-cells using a
machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject
the changed T-cells into the body of the patient.
The goal of this clinical research study is to learn if an investigational type of gene
transfer can be given reliably and safely in patients with advanced B-cell lymphoma. B cells
are a type of white blood cell that fights infection and disease. Lymphoma is a type of
cancer that affects the immune system, including B cells.
The gene transfer involves drawing blood, separating out T cells (white blood cells that
fight infection and disease), changing the T cells' DNA (genetic material) in a specific way,
and returning the changed T cells back to the body.
Researchers want to learn the highest dose of the changed T cells that can be given safely.
Researchers also want to learn how long the changed T cells remain in the participant's body,
and if the changed T cells can reliably treat B-cell lymphoma. Finally, researchers want to
learn if interleukin-2 (IL-2) can help the changed T cells last longer in the body.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Intrexon Corporation National Cancer Institute (NCI) Ziopharm